NCT00083226View on ClinicalTrials.gov

Doxorubicin and Bortezomib in Treating Patients With Liver Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

February 28, 2011

Study Completion Date

August 31, 2012

Conditions
Adult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver CancerRecurrent Adult Primary Liver Cancer
Interventions
DRUG

doxorubicin

Given IV

DRUG

bortezomib

Given IV

Trial Locations (1)

02215

Eastern Cooperative Oncology Group, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00083226 - Doxorubicin and Bortezomib in Treating Patients With Liver Cancer | Biotech Hunter | Biotech Hunter